Crinetics Advances Pediatric Trial for Congenital Adrenal Hyperplasia Treatment
Event summary
- Crinetics dosed the first patient in its BALANCE-CAH Phase 2/3 trial for atumelnant, a novel oral ACTH receptor antagonist, on January 22, 2026.
- The study aims to evaluate safety, efficacy, and pharmacokinetics of atumelnant in pediatric patients with congenital adrenal hyperplasia (CAH).
- Atumelnant is the first and only small molecule ACTH receptor antagonist in late-stage clinical development for CAH.
- Crinetics received Orphan Drug Designation from the FDA for atumelnant in treating classic CAH.
The big picture
Crinetics' initiation of the BALANCE-CAH trial marks a critical step in addressing a significant unmet medical need in pediatric endocrine disorders. The study's success could position atumelnant as a transformative therapy, potentially reshaping the treatment landscape for CAH and other ACTH-related conditions. This aligns with broader industry trends toward targeted, small-molecule therapies for rare endocrine diseases.
What we're watching
- Clinical Efficacy
- How atumelnant's ability to block the ACTH receptor pathway will translate into sustained reductions in key CAH biomarkers.
- Regulatory Pathway
- Whether the Orphan Drug Designation will expedite atumelnant's approval process for pediatric CAH treatment.
- Market Potential
- The pace at which Crinetics can expand atumelnant's indications beyond CAH into other ACTH-dependent conditions like Cushing’s syndrome.